Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects

NCT ID: NCT00926016

Last Updated: 2012-02-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 23 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-06-30
• Study Completion Date: 2010-09-30

Brief Summary

The purpose of this study is to determine if rosiglitazone, a medicine used to treat diabetes, improves response to anti-viral treatment.

Detailed Description

The aim of the study will be to determine if an insulin sensitizing thiazolidinedione (TZD) improves (1) baseline viremia, (2) enhances viral kinetics, (3) improves cytokine profiles and (4) up regulates innate cellular immunity (presumably adaptive immunity is up regulated as well) as measured by the bioactivity of the collected biomarkers.

Conditions

Chronic Hepatitis C

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Blinding Strategy: NONE

Study Groups

pioglitazone

Treatment with pioglitazone 45 mg a day for 3 months

Group Type: ACTIVE_COMPARATOR

Pioglitazone (Actos)

Intervention Type: DRUG

pioglitazone 45 mg a day

No intervention

Monitoring period without pioglitazone for 3 months

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Pioglitazone (Actos)

pioglitazone 45 mg a day

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• HCV-Ab or HCV-RNA by PCR Positive for at least six months (to rule out acute seroconversion)
• Serum positive for HCV-RNA by PCR assay
• Must have insulin resistance, defined as a QUICKI score < 0.35. QUICKI
• Liver biopsy consistent with CHC within 24 months prior to enrollment
• Compensated liver disease with the following minimum hematological, biochemical, and serologic criteria at the Screening Visit (WNL = within normal limits):

• Hemoglobin values of >12 gm/dL for females and >13 gm/dL for males.
• WBC >3,000/ mm3
• Neutrophil count > 1,500/mm3
• Platelets >65,000/ mm3
• Direct bilirubin, within 20% of ULN
• Indirect bilirubin, within normal limits (WNL)
• Albumin >3gm/dL
• Serum creatinine < 20% above the ULN
• TSH WNL
• Alpha fetoprotein value < 100 ng/mL

Exclusion Criteria

• Prior interferon based therapy
• Use of insulin
• Fasting glucose levels > 200 mg/dl
• Women who are pregnant or breast-feeding
• No other thiazolidinedione after liver biopsy and/or during the entire study (
• Hepatitis C of non-genotype 1
• Suspected hypersensitivity to pioglitazone
• Any cause for liver disease other than chronic hepatitis C, insulin resistance, or NAFLD, including but not limited to:

• Hemochromatosis
• Alpha-1 antitrypsin deficiency
• Co-infection with HBV
• Wilson's disease
• Autoimmune hepatitis
• Significant alcohol use
• Drug-related liver disease
• Any condition that would prevent the subject from having a liver biopsy.
• Hemoglobinopathies that could potentially compromise patient safety
• Evidence of advanced liver disease such as history or presence of ascites, bleeding varices, spontaneous encephalopathy.
• Participants with organ transplants other than cornea and hair transplant.
• Any known preexisting medical condition that could interfere with the subject's participation in and completion of the protocol such as:

• Preexisting psychiatric condition, especially severe depression, or a history of severe psychiatric disorder, such as major psychoses, suicidal ideation and/or suicidal attempt are excluded
• Substance abuse, such as alcohol, IV drugs and inhaled drugs
• Alcohol consumption is to be strongly discouraged
• Seizure disorders not controlled with medication
• Significant cardiovascular dysfunction within the past 12 months
• Chronic pulmonary disease with documented pulmonary hypertension
• Immunologically mediated disease [e.g., inflammatory bowel disease (Crohn's disease, ulcerative colitis)], rheumatoid arthritis, idiopathic thrombocytopenia purpura, systemic lupus erythematosis, autoimmune hemolytic anemia, scleroderma, severe psoriasis, clinical cryoglobulinemia with vasculitis
• Any medical condition requiring, or likely to require, chronic systemic administration of steroids during the course of the study
• Evidence of an active or suspected cancer or a history of malignancy where the risk of reoccurrence is ≥ 20% within two years

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The Geneva Foundation

OTHER

Sponsor Role: collaborator

Brooke Army Medical Center

FED

Sponsor Role: lead

Responsible Party

Stephen A Harrison

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Stephen A Harrison, MD

Role: PRINCIPAL_INVESTIGATOR

Brooke Army Medical Center

Locations

Brooke Army Medical Center

San Antonio, Texas, United States

Countries

United States

Other Identifiers

C.2006.152

Identifier Type: -

Identifier Source: org_study_id